Clinical trial · Interventional
Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573 in Solid Tumors
NCT02405065CI-TRIAL-00046525completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objective of this study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose of HM95573.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HM95573 | Drug | Belvarafenib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- HM95573
- description
- single arm
- interventionNames
- Drug: HM95573
Primary outcomes (1)
- measure
- Safety and tolerability
- timeFrame
- Dose limiting Toxicity will be evaluated on Day 28 during Cycle 1
Secondary outcomes (1)
- measure
- Overall rsponse rate
- timeFrame
- 6-12 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must be 20 years of age or older * Subjects who have provided voluntary consent to participate in the study, and signed the written consent document. * Estimated life expectancy of at least 12 weeks * Histologically or cytologically confirmed advanced solid tumor Exclusion Criteria: * Symptomatic or uncontrolled central nervous system metastases * Patients who are unable to take tablets orally or have a clinically significant gastrointestinal disorder, which may interfere with administration, metabolism and absorption of the investigational drug. * Patients who, in the investigator's opinion, are not suitable for the study for any other reason.
References
Publications (0)
Data not yet available
No reference posted for this study.